NCT06809374Completed
Investigation of the Optimal Duration of Neoadjuvant Therapy for Resectable Pancreatic Cancer
Source: ClinicalTrials.gov · Last updated 5 Feb 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
Investigating the Optimal Duration of Neoadjuvant Chemotherapy for Resectable Pancreatic Cancer to Determine the True Surgical Indication.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 100 (actual)
- First submitted
- 30 Jan 2025
- Start date
- 1 Jan 2015
- Primary completion date
- 31 Dec 2024
- Lead sponsor
- Kochi University
- Diseases
- Pancreatic cancer, Childhood cancers
- NCT number
- NCT06809374
What you commit to
- Study type: Observational
- Participants enrolled: 100
- From 1 Jan 2015 to the primary completion date, 31 Dec 2024
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- a body weight loss of greater than 10% during the six months prior to surgery, the presence of distant metastases, or seriously impaired function of vital organs due to respiratory, renal, or heart disease
Who the study is looking for
- radiologically resectable pancreatic cancer patients
Sex: All · Accepts healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.